Feature | April 06, 2012

Rollout of New Oral Anticoagulants Will Drastically Change Clinical Practice

April 6, 2012 — The U.S. anticoagulant market is on the verge of a major shift in clinical practice, transitioning from a market dominated by a single injectable anticoagulant to a highly competitive one dominated by first-in-class novel oral anticoagulants. Companies are vying with each other to introduce novel therapies that offer superior safety, efficacy and convenience to patients and physicians.

New analysis from Frost & Sullivan's Analysis of the Anticoagulant Market research finds that the market earned revenues of $4.7 billion in 2010 and expects it to reach $11.8 billion in 2016.

"Studies reveal that there are currently 2.7 million patients in the United States with atrial fibrillation (AF); however, this may be an underestimation as the actual figure could be as high as 4 million," said Frost & Sullivan senior industry analyst Deborah Toscano. "Lifelong anticoagulant therapy is critical for stroke prevention in these patients, resulting in substantial commercial opportunities."

Warfarin, the long-established gold standard therapy for stroke prevention in AF, carries many significant inherent risks such as bleeding, leaving a very narrow therapeutic window.

The market experienced a robust growth period following the launch of Pradaxa (dabigatran), an oral direct thrombin inhibitor (DTI), in late 2010, and Xarelto (rivaroxaban), an oral factor Xa inhibitor, in 2011. A second growth period is expected upon the anticipated launch of Eliquis (apixaban), an oral factor Xa inhibitor, in mid-2012. Edoxaban, an oral factor Xa inhibitor, is also in the pipeline. These agents are poised to dominate the market for stroke prevention in AF, a very large and partially untapped market. They are also likely to grab substantial market share from the parenteral anticoagulants for prophylaxis of venous thromboembolism in orthopedic joint replacement surgery.

With the approval of Pradaxa and Xarelto and the imminent approval of their successors, the bar has been significantly raised for the anticoagulant market. Superiority to warfarin is paramount for new drug approval and market uptake. Patient and clinician acceptance will depend on strong data showing improvements in efficacy and lower risk of bleeding.

There is a fine line between the prevention of thrombosis and uncontrollable bleeding. Most often, bleeding issues or other safety concerns may not arise until late-stage clinical trials, or only in certain patient populations, after significant investments in drug development have been made. In addition, bleeding issues or other safety concerns may surface in the future, particularly if the bleeding risk of the real-world population differs from that studied in clinical trials, leading to black-box warnings or market withdrawal. One of the shortcomings of oral anticoagulants is the lack of a strategy for reversal in case of emergency or uncontrolled bleeding.

"The oral anticoagulants are ideal for chronic therapy with their easy administration," said Toscano. "However, the ability to quickly reverse the anticoagulant action in the event of an emergency is a critical, unmet need."

Newcomers to the market that can address this issue will resolve the key shortfall of chronic anticoagulation therapy. Their drugs are likely to see rapid adoption into clinical practice.

For more information: www.pharma.frost.com

Related Content

atrial fibrillation, stroke risk, aspirin vs blood thinners, JACC study
News | Antiplatelet and Anticoagulation Therapies| June 24, 2016
More than 1 in 3 atrial fibrillation (AF) patients at intermediate to high risk for stroke are treated with aspirin...
Biotronik, CardioStim 2016 Innovation Award, MRI AutoDetect, Ilivia ICDs
News | EP Lab| June 23, 2016
Biotronik announced it was the winner of the Cardiostim Innovation Award in the category “Best Practice Improvement”...
Zoll LifeVest wearable defibrillator, WEARIT-II Registry results, CardioStim EuroPace 2016
News | Defibrillator Monitors| June 21, 2016
Zoll Medical Corp. announced that patients experience a high one-year survival rate following use of the LifeVest...
News | Implantable Cardioverter Defibrillators (ICD)| June 14, 2016
Medtronic plc announced results from several feasibility studies evaluating a new approach to implantable cardioverter...
Medtronic, Micra TPS pacemaker, Global Clinical Trial, Cardiostim 2016
News | Pacemakers| June 09, 2016
Medtronic plc announced new results from the Medtronic Micra Transcatheter Pacing System (TPS) Global Clinical Trial in...
EPIC Alliance, women in electrophysiology, cardiac rhythm management, Cardiostim 2016 conference
News | EP Lab| June 08, 2016
Physicians presented original research and real-world clinical evidence at a symposium organized by the...
Medtronic, Micra TPS, transcatheter pacing system, pacemaker, Jersey Shore University Medical Center, New Jersey first
News | Pacemakers| June 06, 2016
Jersey Shore University Medical Center, part of Meridian CardioVascular Network, is the first hospital in New Jersey to...
female patients, atrial fibrillation, blood thinning therapy, AFDST, decision support tool, Cincinnati
News | Antiplatelet and Anticoagulation Therapies| June 02, 2016
Female atrial fibrillation patients are less likely than their male counterparts to receive blood thinning therapies to...
Biotronik, CardioMessenger Smart, remote monitoring, ICD, pacemaker
Technology | EP Device Monitoring Systems| June 01, 2016
Biotronik announced the launch of CardioMessenger Smart in the United States. CardioMessenger Smart is a portable...
anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies| May 25, 2016
Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected...
Overlay Init